Stock Price Quote

MANKIND PHARMA LTD.

NSE : MANKINDBSE : 543904ISIN CODE : INE634S01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE2573.65-9.9 (-0.38 %)
PREV CLOSE ( ) 2583.55
OPEN PRICE ( ) 2598.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4296
TODAY'S LOW / HIGH ( )2555.55 2611.10
52 WK LOW / HIGH ( )1910.1 3050
NSE2579.50-8.9 (-0.34 %)
PREV CLOSE( ) 2588.40
OPEN PRICE ( ) 2588.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 2579.50 (92)
VOLUME 459548
TODAY'S LOW / HIGH( ) 2554.10 2613.80
52 WK LOW / HIGH ( )1901.05 3054.8
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 03-07 1991
Management Info
Ramesh Juneja - Chairman Rajeev Juneja - Managing Director
Registered Office

Address 208,Okhla Industrial Estate,Phase - 111,
New Delhi,
Delhi-110020

Phone 011-46846700

Email contact@mankindpharma.com

Website www.mankindpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

15Apr Mankind Pharma gets nod to incorporate
Mankind Pharma has received approval from board of directors to incorpor..
03Apr Mankind Pharma informs about complianc
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Reg..
01Mar Mankind Pharma informs about disclosure
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Ob..
10Feb Mankind Pharma informs about outcome o
Mankind Pharma has informed that the Board appointed Committee of Indepe..
15Jan Mankind Pharma informs about update
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Ob..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit4163.818234.11
Gross Profit 5242.5 22595.68
Operating Profit 8107.525917.44
Net Sales 23965.792648.09

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  8942.35 (2.41%)
M.Cap ( in Cr)22137.50
RPG Life Sciences (BSE)
peergroup  2273.40 (4.41%)
M.Cap ( in Cr)3699.28
Sanofi India (BSE)
peergroup  6362.00 (0.88%)
M.Cap ( in Cr)14652.43
Pfizer (BSE)
peergroup  4244.00 (1.24%)
M.Cap ( in Cr)19392.46
Samrat Pharmachem (BSE)
peergroup  405.40 (12.50%)
M.Cap ( in Cr)125.44

Shareholding Pattern

PROMOTERS 72.7%
MUTUAL FUNDS/UTI 7.67%
NON-INSTITUTION 2.93%
FI/BANKS/INSURANCE 2.23%
GOVERNMENT 0%
FII 0%

About Mankind Pharma Ltd.

Mankind Pharma Ltd. was incorporated in the year 1991. Its today's share price is 2573.65. Its current market capitalisation stands at Rs 106003.8 Cr. In the latest quarter, company has reported Gross Sales of Rs. 96239.26 Cr and Total Income of Rs.95314.48 Cr. The company's management includes Hitesh Kumar Jain, Vivek Kalra, Bharat Anand, Vijaya Sampath, T P Ostwal, Satish Kumar Sharma, Sheetal Arora, Rajeev Juneja, Ramesh Juneja.

It is listed on the BSE with a BSE Code of 543904 , NSE with an NSE Symbol of MANKIND and ISIN of INE634S01028. It's Registered office is at 208,Okhla Industrial Estate,Phase - 111New Delhi-110020, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bhagi Bhardwaj Gaur & Co, Deloitte Haskins & Sells LLP, Goel Gaurav & Co, SR Batliboi & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.